Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

7RT5

Crystal structure of KRAS G12D with compound 36 (4-[(1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl]-7-(8-ethynyl-7-fluoronaphthalen-1-yl)-8-fluoro-2-{[(4s,7as)-tetrahydro-1H-pyrrolizin-7a(5H)-yl]methoxy}pyrido[4,3-d]pyrimidine) bound

Summary for 7RT5
Entry DOI10.2210/pdb7rt5/pdb
Related7RPZ
DescriptorIsoform 2B of GTPase KRas, GUANOSINE-5'-DIPHOSPHATE, 4-[(1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl]-7-(8-ethynyl-7-fluoronaphthalen-1-yl)-8-fluoro-2-{[(4s,7as)-tetrahydro-1H-pyrrolizin-7a(5H)-yl]methoxy}pyrido[4,3-d]pyrimidine, ... (5 entities in total)
Functional Keywordsoncoprotein, g12d, gdp, gtpase, kras4b, hydrolase-inhibitor complex, hydrolase/inhibitor
Biological sourceHomo sapiens (Human)
Total number of polymer chains1
Total formula weight20398.88
Authors
Gunn, R.J.,Thomas, N.C.,Xiaolun, W.,Lawson, J.D.,Marx, M.A. (deposition date: 2021-08-12, release date: 2021-12-22, Last modification date: 2023-10-18)
Primary citationWang, X.,Allen, S.,Blake, J.F.,Bowcut, V.,Briere, D.M.,Calinisan, A.,Dahlke, J.R.,Fell, J.B.,Fischer, J.P.,Gunn, R.J.,Hallin, J.,Laguer, J.,Lawson, J.D.,Medwid, J.,Newhouse, B.,Nguyen, P.,O'Leary, J.M.,Olson, P.,Pajk, S.,Rahbaek, L.,Rodriguez, M.,Smith, C.R.,Tang, T.P.,Thomas, N.C.,Vanderpool, D.,Vigers, G.P.,Christensen, J.G.,Marx, M.A.
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS G12D Inhibitor.
J.Med.Chem., 65:3123-3133, 2022
Cited by
PubMed Abstract: KRAS, the most common oncogenic KRAS mutation, is a promising target for the treatment of solid tumors. However, when compared to KRAS, selective inhibition of KRAS presents a significant challenge due to the requirement of inhibitors to bind KRAS with high enough affinity to obviate the need for covalent interactions with the mutant KRAS protein. Here, we report the discovery and characterization of the first noncovalent, potent, and selective KRAS inhibitor, MRTX1133, which was discovered through an extensive structure-based activity improvement and shown to be efficacious in a KRAS mutant xenograft mouse tumor model.
PubMed: 34889605
DOI: 10.1021/acs.jmedchem.1c01688
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.29 Å)
Structure validation

227344

PDB entries from 2024-11-13

PDB statisticsPDBj update infoContact PDBjnumon